Structure Therapeutics Inc.
NASDAQ:GPCRBiotechnology
+$0.39 today
- Market cap
- $999.36M
- Beta
- -1.42
- P/E (TTM)
- -19.3
- EPS (TTM)
- -$2.35
Volume 1.10M
Average 0.87M
GPCR Income Tax Expense
Income taxes recognized for the period, including current and deferred tax.
Structure Therapeutics Inc.NASDAQ: GPCR
Income Tax Expense · Q2 FY2026 · quarter ended Jun 2026
Income tax expense growth accelerates
Q2 FY2026 income tax expense of $234K rose 68.3% year over year, ahead of the +51.1% change in trailing-twelve-month income tax expense. Sequentially, it rose 22.8% from the prior quarter. Over 3 fiscal years it compounded at +211.7% a year.
Context
- Income tax expense increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +68.3% holds above the trailing-twelve-month pace of +51.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Tax Expense history
USD · from the income statement
- Latest · FY2025
- 515K USD
- Year-over-year change
- +66.1%
- 4-year CAGR
- +22.2%
| Period | Period end | Income Tax Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 515K | +66.1% |
| FY2024 | 2024-12-31 | 310K | +31.4% |
| FY2023 | 2023-12-31 | 236K | +1288.2% |
| FY2022 | 2022-12-31 | 17K | -92.6% |
| FY2021 | 2021-12-31 | 231K | — |
Income Tax Expense vs competitors
How GPCR compares with its peers on the latest reported figures
- GPCR's LTM Jun 2026 income tax expense of $702.57K is the highest of the 8 companies compared; the peer median is $0.
- Its year-over-year change of +51.1% is the highest of 3, against a peer median of -1030.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $702.57K | +51.1% | +211.7% | — | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
KLRAKailera Therapeutics, Inc. | FY2025 | $0 | — | — | — |
| LTM Jun 2026 | $0 | — | — | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $0 | — | — | 0.0% |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | -$3.3M | -1961.9% | — | 3.4% |
| Peer median (excluding GPCR) | $0 | -1030.9% | — | 0.0% | |
Competitors are the stored peer set for GPCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 3.9M |
| Gross Profit | 0 | 0 | 0 | 0 | (3.9M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 29.11M | 36.19M | 70.1M | 108.81M | 225.26M |
| Selling, General & Admin | 8.59M | 16.37M | 32.67M | 49.41M | 61.55M |
| Operating Expenses | 37.7M | 52.56M | 102.78M | 158.23M | 283.67M |
| Depreciation & Amortization | 72K | 277K | 295K | 992K | 3.9M |
| EBITDA | (37.62M) | (51.03M) | (75.7M) | (121.22M) | (136.79M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (37.7M) | (52.56M) | (102.78M) | (158.23M) | (287.57M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 122 | 1.26M | 13.38M | 36.03M | 35.97M |
| Interest Expense | 122.16K | 0 | 13.39M | 0 | 0 |
| Other Income / Expenses | (122K) | 1.26M | 13.39M | 36.01M | 146.51M |
| Income Before Tax | (37.82M) | (51.3M) | (89.38M) | (122.22M) | (140.69M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 231K | 17K | 236K | 310K | 515K |
| Net Income | (40.01M) | (51.32M) | (89.62M) | (122.53M) | (141.2M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.20) | (1.44) | (2.43) | (2.34) | (2.40) |
| EPS (Diluted) | (1.20) | (1.44) | (2.43) | (2.34) | (2.40) |
| Weighted Avg Shares | 36.59M | 36.59M | 36.73M | 52.64M | 59.2M |
| Weighted Avg Shares (Diluted) | 36.59M | 36.59M | 36.73M | 52.64M | 59.2M |
Structure Therapeutics Inc.
NASDAQ:GPCR
Intrinsic Alpha fair value
Locked
Current Price
$17.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.